Detection method of impurity C in peramivir injection

Detection of impurity C in paramivir injection by high performance liquid chromatography solved the detection problems in the prior art, established a systematic detection method, and improved the level of drug quality control.

CN115791999BActive Publication Date: 2024-11-08HAINAN HULUWA PHARMA GRP CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202211347447.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-31
Publication Date
2024-11-08
Estimated Expiration
2042-10-31

AI Technical Summary

Technical Problem

The prior art has failed to effectively detect impurity C in paramivir injection, and lacks relevant quality standards and testing methods, which affects drug quality control.

Method used

High performance liquid chromatography is used to detect impurity C in paramivir injection, and prepare corresponding solution preparation methods, including impurity C positioning solution, supply and supply The test solution and the control solution were systematically verified.

Benefits of technology

An effective detection method for impurity C of the paramivir injection solution was established, and the detection reliability was ensured through special attributes, linearity and range, accuracy test, repeatability test, intermediate precision test, solution stability test and durability test. and applicability, improve the level of drug quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115791999B_ABST
    Figure CN115791999B_ABST
Patent Text Reader

Abstract

The present invention provides a method for detecting impurity C of peramivir injection. The method for detecting impurity C of peramivir injection comprises the following steps: using high performance liquid chromatography for detection, and the measuring conditions include: using protein bonded silica gel as a filler for the chromatographic column, detecting wavelength: 203-207nm, column temperature: 18-22°C, flow rate: 0.2-0.4ml / min. The present invention adopts a reversed-phase chiral chromatography system to establish a method for detecting impurity C of peramivir injection, and systematically verifies the method, passes the investigations of specificity, linearity and range, accuracy test, repeatability test, intermediate precision test, solution stability test and durability test, and can be well applied to the detection of impurity C of peramivir injection, which is helpful to improve the quality control level of peramivir injection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of impurity detection of Peramivir injection, and in particular to a method for detecting impurity C of Peramivir injection. Background Art

[0002] Peramivir is a new type of anti-influenza virus drug. Existing clinical trial data have shown that it is effective against influenza A and B.

[0003] Peramivir API Synthesis Route:

[0004]

[0005] The specific synthesis method is that the starting material undergoes ring opening and reduction reaction under the action of reducing agent sodium borohydride to generate intermediate Ⅰ; intermediate Ⅰ and acetic anhydride undergo esterification reaction to generate intermediate Ⅱ; intermediate Ⅱ undergoes hydrolysis reaction under the action of sodium hydroxide to generate intermediate Ⅲ; intermediate Ⅲ is deprotected under the action of hydrochloric acid to generate intermediate Ⅳ, and the unseparated intermediate Ⅳ directly reacts with the starting material Ⅱ to generate crude peramivir, and finally undergoes crystal transformation to generate peramivir. Its important dosage form is intravenous injection. The impurity C of peramivir injection mainly comes from raw material process impurities. The pharmacopoeias of various countries have not included the quality standards of peramivir injection, let alone the detection method of impurity C of peramivir injection; the impurity C detection method in the quality standards of peramivir raw material suppliers adopts a normal phase chromatography system. This product is an injection and has poor solubility in a normal phase chromatography system. However, only the State Food and Drug Administration has included peramivir sodium chloride injection (100ml: peramivir C 15 H 28 The standard for impurity C in peramivir injection (YBH01412013) does not record the detection method for impurity C in peramivir injection.

[0006] The chemical name of impurity C (enantiomer) is (1R,2R,3S,4S)-3-[(1R)-1-(acetylamino)-2-ethylbutyl]-4-guanidine-2-hydroxycyclopentanecarboxylic acid trihydrate, and the molecular formula is C 15 H 28 N4O4·3H2O, molecular weight 382.45, structure as follows:

[0007] Summary of the invention

[0008] In view of this, the present invention proposes a method for detecting impurity C in peramivir injection to solve the above technical problems.

[0009] The technical solution of the present invention is achieved in this way:

[0010] The method for detecting impurity C in peramivir injection comprises the following steps: detecting by high performance liquid chromatography, and the measuring conditions include: chromatographic column: AGP, detection wavelength: 203-207 nm, column temperature: 18-22 °C, flow rate: 0.2-0.4 ml / min.

[0011] Furthermore, the phosphate buffer contains 4.75-5.25 mmol / L diammonium hydrogen phosphate and 4.75-5.25 mmol / L monoammonium phosphate per 1 L of phosphate buffer.

[0012] Further, the solution preparation includes:

[0013] Impurity C localization solution: Take impurity C, weigh accurately, add solvent to dissolve and dilute to a solution containing 0.015-0.025 mg per 1 ml;

[0014] Test solution: Accurately measure the peramivir injection solution, dilute it with solvent to a solution containing 0.4-0.6 mg of peramivir per 1 ml, and mix well;

[0015] Control solution: Accurately measure the test solution, dilute it with solvent to a solution containing 0.8-1.2 μg of peramivir per 1 ml, and mix well.

[0016] Furthermore, the solvent is water.

[0017] Further, the determination method: accurately measure the test solution, control solution and blank solvent, inject them into the liquid chromatograph respectively, and record the chromatogram.

[0018] Furthermore, the injection volume is 3 to 5 μl.

[0019] Further mobile phase: 5mmol / L diammonium hydrogen phosphate and 5mmol / L diammonium hydrogen phosphate buffer.

[0020] Furthermore, the specifications of the chromatographic column are 150 mm×4.0 mm, 5 μm.

[0021] Further, detection wavelength: 205 nm, column temperature: 20° C., flow rate: 0.3 ml / min, injection volume: 4 μl.

[0022] Further, the impurity C localization solution: take the impurity C, weigh it accurately, add solvent to dissolve it and dilute it to a solution containing 0.02 mg per 1 ml;

[0023] Test solution: Accurately measure the peramivir injection solution, dilute it with solvent to a solution containing 0.5 mg of peramivir per 1 ml, and mix well;

[0024] Control solution: Accurately measure the test solution, dilute it with solvent to a solution containing 1 μg of peramivir per 1 ml, and mix well.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention adopts a reversed-phase chiral chromatography system to establish a detection method for impurity C of peramivir injection, and conducts systematic methodological verification on the method, passes inspections such as specificity, linearity and range, accuracy test, repeatability test, intermediate precision test, solution stability test and durability test, and can be well applied to the detection of impurity C of peramivir injection, which is helpful to improve the quality control level of peramivir injection. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 HPLC spectrum of solvents in the specificity test of the method of the present invention;

[0028] Figure 2 HPLC spectrum of blank auxiliary materials in the specificity test of the present invention;

[0029] Figure 3 HPLC spectrum of the solution for the location of impurity O in the specificity test of the present invention;

[0030] Figure 4 HPLC spectrum of the solution for the location of impurity Q in the specificity verification test of the present invention;

[0031] Figure 5 HPLC spectrum of the solution for localization of impurity S in the specificity verification test of the present invention;

[0032] Figure 6 HPLC spectrum of the solution for locating impurity T in the specificity verification test of the present invention;

[0033] Figure 7 HPLC spectrum of the spiked test sample solution in the specificity verification test of the present invention;

[0034] Figure 8 The present invention verifies the specificity of the test solution HPLC spectrum;

[0035] Fig. 9 HPLC spectrum of the control solution in the specificity verification test of the present invention;

[0036] Fig.10 HPLC spectrum of the spiked mixed solution in the specificity verification test of the present invention;

[0037] Fig.11 is the linearity graph of peramivir in the linearity test of the present invention;

[0038] Fig.12It is the linear graph of impurity C in the linear test of the present invention. DETAILED DESCRIPTION

[0039] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.

[0040] Unless otherwise specified, the experimental methods used in the embodiments of the present invention are all conventional methods.

[0041] Unless otherwise specified, the materials, reagents, etc. used in the embodiments of the present invention can be obtained from commercial sources.

[0042] Example

[0043] (I) Detection method of impurity C in peramivir injection

[0044] High performance liquid chromatography

[0045] Chromatographic column: AGP, 150mm×4.0mm, 5μm

[0046] Detection wavelength: 205nm

[0047] Column temperature: 20℃

[0048] Flow rate: 0.3ml / min

[0049] Injection volume: 4 μl

[0050] Mobile phase: 5mmol / L diammonium phosphate and 5mmol / L diammonium phosphate buffer

[0051] Solvent: Water

[0052] Solution preparation:

[0053] Impurity C localization solution: Take an appropriate amount of impurity C, weigh it accurately, add solvent to dissolve it and dilute it to a solution containing approximately 0.02 mg per 1 ml.

[0054] Test solution: Accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric flask, add solvent to dilute to the scale, and shake well.

[0055] Control solution: Accurately measure 1 ml of the test solution, place it in a 20 ml volumetric flask, dilute it to the scale with solvent, shake well, accurately measure 1 ml, place it in 25 ml, dilute it to the scale with solvent, and shake well.

[0056] Determination method: Accurately measure 4 μl of the test solution, control solution and blank solvent, respectively, inject them into the liquid chromatograph, and record the chromatogram.

[0057] Limit: Calculated by the self-control method without adding correction factors, impurity C shall not exceed 0.2%.

[0058] (II) The analytical method was fully validated in accordance with the four guidelines of the 2020 edition of the Chinese Pharmacopoeia. The method validation included: specificity, linearity and range, accuracy test, repeatability test, intermediate precision test, solution stability test and durability test. The sample information used for validation is shown in Table 1.

[0059] Table 1 Verification sample information

[0060]

[0061] 1. Specificity test

[0062] 1.1 Brief Introduction

[0063] The specificity study of the method examines peak identification and selectivity. By positioning each impurity, it is ensured that the separation degree between impurity C and the main peak meets the standard, each impurity can be well separated from the main peak and impurity C, and the auxiliary material solution and solvent do not interfere with the determination. 1.2 Operation method:

[0064] Blank excipient solution: Accurately measure 1 ml of the complete excipient solution, place it in a 20 ml volumetric flask, dilute to the mark with solvent, and shake well.

[0065] Impurity O positioning solution: Take about 2 mg of impurity O, accurately weigh it, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, as the stock solution of impurity O, accurately measure 1 ml, place it in a 20 ml volumetric flask, dilute to the scale with solvent, and shake well.

[0066] Impurity Q localization solution: Take about 2 mg of impurity Q, accurately weigh it, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, as the stock solution of impurity Q, accurately measure 1 ml, place it in a 20 ml volumetric flask, dilute to the scale with solvent, and shake well.

[0067] Impurity S localization solution: Take about 2 mg of impurity S, accurately weigh it, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well as the stock solution of impurity S, accurately measure 1 ml, place it in a 20 ml volumetric flask, dilute to the scale with solvent, and shake well.

[0068] Impurity T positioning solution: Take about 2 mg of impurity T, accurately weigh it, put it in a 10 ml volumetric bottle, add solvent to dissolve and dilute to the scale, shake well, as the stock solution of impurity T, accurately measure 1 ml, put it in a 20 ml volumetric bottle, dilute to the scale with solvent, shake well. The structural formulas of the above impurities impurity O, impurity Q, impurity S, and impurity T are as follows in Table 2:

[0069] Table 2

[0070]

[0071] Impurity C localization solution: Take about 5 mg of impurity C, accurately weigh it, place it in a 50 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, as the impurity C stock solution, accurately measure 5 ml, place it in a 25 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well.

[0072] Impurity mixed solution: Accurately measure 1 ml of impurity O, Q, S, and T stock solutions respectively, place them in a 10 ml volumetric flask, add solvent to dilute to the scale, and shake well.

[0073] Test solution: Accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric flask, add solvent to dilute to the scale, and shake well.

[0074] Spiked test solution: Accurately measure 1 ml each of Peramivir Injection and Impurity C Location Solution, place in a 20 ml volumetric flask, add solvent to dilute to the scale, and shake well.

[0075] Control solution: Accurately measure 1 ml of the spiked test solution, place it in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place it in 25 ml, dilute to the scale with solvent, shake well.

[0076] Spiked mixed solution: Accurately measure 1 ml of peramivir injection, 1 ml of impurity mixed solution and 1 ml of impurity C localization solution, place in a 20 ml volumetric flask, add solvent to dilute to the scale, shake well, and use as the spiked mixed test solution.

[0077] Accurately measure 4 μl of the blank solvent, blank excipient solution, test solution, spiked test solution, control solution, spiked mixed solution and each impurity location solution, respectively, and inject them into the liquid chromatograph to record the chromatogram. The results are shown in Table 3 and Figure 1-10 .

[0078] 1.3 Test results

[0079] Table 3 Specificity test results

[0080]

[0081] 1.4 Conclusion

[0082] Blank solvent and blank auxiliary material solution do not interfere with the determination. In the spiked mixed solution, impurities O and Q do not interfere with the determination of impurity C and the main component. The peak times of impurities S and C coincide with each other, and the impurities are strictly controlled to calculate the impurity mass. The separation degree of impurity T and impurity S / C is 1.41, which is less than 1.5 but greater than 1.2, and baseline separation can be achieved. The specificity of this method is good.

[0083] 2 Linearity test

[0084] 2.1 Brief Introduction

[0085] Combined with the impurity analysis of the synthetic process of this product, a linear test was conducted on impurity C. In the linear test, the linear correlation coefficient r should be greater than 0.990, and the ratio of the Y-axis intercept to the 100% theoretical concentration response value should be less than 25%.

[0086] 2.2 Operation Method

[0087] Linear stock solution: Take 11.5 mg of peramivir trihydrate, accurately weigh, place in a 100 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, accurately measure 1 ml and 1 ml of impurity C stock solution under the exclusive test item, place in a 50 ml volumetric flask, dilute to the scale with solvent, shake well, as the linear stock solution.

[0088] Accurately measure 1ml, 3ml, 5ml, 6ml and 7.5ml of the linear stock solution respectively and place them into different 10ml volumetric flasks, dilute to the scale with solvent, shake well and use them as 20%, 60%, 100%, 120% and 150% linear solutions respectively.

[0089] Accurately measure 4 μl of each of the above 20%, 60%, 100%, 120% and 150% linear solutions, inject them into the liquid chromatograph, and record the chromatogram. With the concentration as the abscissa and the peak area as the ordinate, perform linear regression using the least squares method and calculate the correlation coefficient. The results are shown in Table 4.

[0090] 2.3 Test results

[0091] Table 4 Linearity test results

[0092]

[0093] 2.4 Conclusion

[0094] The linear correlation coefficient r of peramivir is 0.99996, which is greater than 0.990, and the ratio of the Y-axis intercept to the 100% theoretical concentration response value is 0.46%, which is less than 25%; the linear correlation coefficient r of impurity C is 0.99712, which is greater than 0.990, and the ratio of the Y-axis intercept to the 100% theoretical concentration response value is 1.30%, which is less than 25%. The correction factor of impurity C is 1.05, which is within the range of 0.9 to 1.1, so the self-control method without adding the correction factor can be used for determination.

[0095] 3. Limit of Quantitation and Limit of Detection Tests

[0096] 3.1 Brief Introduction

[0097] The signal-to-noise ratio of each peak in the quantitative limit solution should be greater than 10, the RSD of the retention time of each peak should be less than 1.0%, the RSD of the peak area should be less than 10%, and the quantitative limit should be less than 50% of the limit or the reporting limit (the minimum value). The signal-to-noise ratio of each peak in the quantitative limit solution should be greater than 3.

[0098] 3.2 Operation method

[0099] Quantitation limit solution: Accurately measure 5 ml of 20% linear solution, place it in a 10 ml volumetric flask, add water to dilute to the scale, and shake well.

[0100] Detection limit solution: Accurately measure 5 ml of the quantitative limit solution, place it in a 10 ml volumetric flask, add water to dilute to the scale, and shake well.

[0101] Accurately measure 4 μl of the quantitative limit solution and the detection limit solution and inject them into the liquid chromatograph to record the chromatogram. The results are shown in Table 5.

[0102] 3.3 Test results

[0103] Table 5 Results of limit of quantitation and limit of detection tests

[0104]

[0105] 3.4 Conclusion

[0106] The quantitative limit solution concentration of impurity C is 0.103μg / ml, the limit is 0.02%, less than 0.05%, repeated 6 times, the minimum signal-to-noise ratio is 12.71, greater than 10; the RSD of retention time is 0.11%, less than 1%; the RSD of peak area is 5.59%, less than 10%, which meets the requirements. The quantitative limit solution concentration of peramivir is 0.115μg / ml, the limit is 0.02%, less than 0.05%, repeated 6 times, the minimum signal-to-noise ratio is 13.20, greater than 10; the RSD of retention time is 0.08%, less than 1%; the RSD of peak area is 4.75%, less than 10%, which meets the requirements. In the detection limit solution, the signal-to-noise ratios of impurity C and peramivir are 5.96 and 6.63, respectively, greater than 3, which meets the requirements.

[0107] 4 Accuracy test

[0108] 4.1 Brief Introduction

[0109] Combined with the impurity analysis of the synthetic process of this product, we conducted an accuracy study on impurity C, using 50%, 100%, and 150% concentrations to examine its accuracy to ensure the accuracy of its test results.

[0110] 4.2 Operation Method

[0111] Reference solution: Accurately measure 1 ml of the impurity C localization solution under the dedicated test item, place it in a 20 ml volumetric bottle, add solvent to quantitatively dilute to the scale, and shake well. Prepare two copies in parallel.

[0112] Blank test solution: Accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric flask, add solvent to dilute to the scale, and shake well.

[0113] 50% recovery solution: accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric bottle, then accurately add 0.5 ml of Impurity C Location Solution under the exclusive test item, dilute to scale with solvent, shake well, dilute to scale with solvent, shake well. (Prepare 3 portions in parallel)

[0114] 100% recovery solution: accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric bottle, then accurately add 1 ml of Impurity C Location Solution under the exclusive test item, dilute to scale with solvent, shake well, dilute to scale with solvent, shake well. (Prepare 3 portions in parallel)

[0115] 150% recovery solution: accurately measure 1 ml of Peramivir Injection, place in a 20 ml volumetric bottle, then accurately add 1.5 ml of Impurity C Location Solution under the exclusive test item, dilute to scale with solvent, shake well, dilute to scale with solvent, shake well. (Prepare 3 portions in parallel)

[0116] Accurately measure 4 μl of each of the above solutions, inject them into the liquid chromatograph, and record the chromatogram. The results are shown in Table 6.

[0117] 4.3 Test results

[0118] Table 6 Accuracy test results

[0119]

[0120] 4.4 Conclusion:

[0121] The average recovery rate of the 50%-150% recovery solution was 94.0%, and in the range of 80%-120%, the RSD was 2.77%, which was less than 10%, and the accuracy was good.

[0122] 5 Durability test

[0123] 5.1 Overview

[0124] The effects of small changes in chromatographic parameters and changes in instrumental chromatographic behavior on the test results were investigated. The tolerance level to which the test results would not be affected was determined by changes in flow rate of ±0.1ml / min, column temperature of ±2℃, and detection wavelength of ±2nm.

[0125] 5.2 Operation Method

[0126] Blank excipient solution: Accurately measure 1 ml of the complete excipient solution, place it in a 20 ml volumetric flask, dilute to the mark with solvent, and shake well.

[0127] Spiked mixed solution: Accurately measure 1 ml of peramivir injection, 1 ml of impurity mixed solution under the exclusive test item, and 1 ml of impurity C positioning solution under the exclusive test item, place them in a 20 ml volumetric flask, add solvent to dilute to the scale, shake well, and use as the spiked mixed solution.

[0128] Control solution: Accurately measure 1 ml of the spiked mixed solution, place it in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place it in 25 ml, dilute to the scale with solvent, shake well.

[0129] Accurately measure 4 μl of the above spiked mixed solution, control solution, blank excipient solution and blank solvent, and inject them into the liquid chromatograph under the conditions of flow rate change ±0.1 ml / min, column temperature change ±2°C, and detection wavelength change ±2 nm, and record the chromatogram. The results are shown in Table 7.

[0130] 5.3 Test results

[0131] Table 7 Durability test results of spiked mixed solution

[0132]

[0133]

[0134] 5.4 Conclusion

[0135] In the durability test, under the conditions of flow rate change of ±0.1ml / min, column temperature change of ±2℃, and detection wavelength change of ±2nm, the separation degree between impurity C and the main peak in the spiked mixed solution was at least 1.97, which was greater than 1.5; the maximum change rate of the detection amount of impurity C was 14.51%, which was less than 20%, and the durability was good.

[0136] 6 Repeatability test

[0137] 6.1 Overview

[0138] Repeatability was verified by preparing 6 test sample solutions to verify that the method had good precision.

[0139] 6.2 Operation Method

[0140] The preparation of the impurity C localization solution is the same as that of the specificity test.

[0141] Spiked test solution: Accurately measure 1 ml of Peramivir Injection and place it in a 20 ml volumetric flask. Then accurately add 1 ml of Impurity C Location Solution, dilute to the mark with solvent, shake well, and use as the spiked test solution. Prepare 6 portions in parallel

[0142] Control solution: Accurately measure 1 ml of the spiked test solution, place it in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place it in 25 ml, dilute to the scale with solvent, shake well.

[0143] Accurately measure 4 μl of the blank solvent, spiked test solution and control solution, respectively, and inject them into the liquid chromatograph to record the chromatogram. The results are shown in Table 8.

[0144] 6.3 Test results

[0145] Table 8 Repeatability test results

[0146]

[0147] 6.4 Conclusion

[0148] In the repeatability test, the RSD of the main peak area of ​​5 consecutive reference solution-1 was 1.43%, less than 2.0%, and the RSD of the detection amount of impurity C in 6 spiked test solutions was 1.09%, less than 20%, with good repeatability.

[0149] 7. Intermediate precision test

[0150] 7.1 Brief Introduction

[0151] In order to examine the impact of random variation factors on precision, another analyst independently established a system to examine the precision of the measurement method.

[0152] 7.2 Operation Method

[0153] According to the above repeatability test method, the content of the same batch of samples was determined on different dates, using different instruments and by different operators, and the operation was repeated 6 times.

[0154] Accurately measure 4 μl of the blank solvent, spiked test solution and control solution, respectively, and inject them into the liquid chromatograph to record the chromatogram. The results are shown in Table 9.

[0155] 7.3 Test results

[0156] Table 9 Intermediate precision test results

[0157]

[0158] 7.4 Conclusion

[0159] In the intermediate precision test, the RSD of the main peak area of ​​5 consecutive reference solution-1 was 1.65%, less than 2%, and the RSD of the detection amount of impurity C in 6 spiked test solutions was 1.96%, less than 20%, and the intermediate precision was good. The RSD of the detection amount of impurity C in 12 spiked test solutions was 4.06%, less than 30%, and the precision was good.

[0160] 8 Solution stability test

[0161] 8.1 Overview

[0162] Investigate how the solution changes over time when placed at room temperature, and provide a basis for the duration of the test solution placement in future tests.

[0163] 8.2 Operation Method

[0164] The preparation of the impurity C localization solution is the same as that of the specificity test.

[0165] Spiked test solution: Accurately measure 1 ml of Peramivir Injection and place it in a 20 ml volumetric flask, then accurately add 1 ml of Impurity C Location Solution, dilute to the mark with solvent, and shake well. Add solvent to dilute to the mark, shake well, and use as the spiked test solution.

[0166] Control solution: Accurately measure 1 ml of the spiked test solution, place it in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place it in 25 ml, dilute to the scale with solvent, shake well.

[0167] At room temperature, accurately measure 4 μl of the blank solvent, spiked test solution and control solution, respectively, and inject them into the liquid chromatograph to record the chromatogram. The results are shown in Table 10.

[0168] Calculation formula:

[0169]

[0170] Where A I The peak area of ​​the peak in the chromatogram at different times; A0 is the peak area of ​​the peak in the chromatogram at 0h.

[0171] 8.3 Test results

[0172] Table 10 Solution stability test results

[0173]

[0174] 8.4 Conclusion

[0175] Within 24 hours, the maximum change rate of the peak area of ​​the main peak in the control solution is 2.49%, which is less than 20%. The control solution can be considered stable within 24 hours. Within 24 hours, the maximum change rate of the peak area of ​​impurity C in the spiked test solution is 2.17%, which is less than 20%. The spiked test solution can be considered stable within 24 hours.

[0176] 9. Durability

[0177] 9.1 Test methods

[0178] Under the conditions of flow rate change ±0.1ml / min, column temperature change ±2℃, and detection wavelength change ±2nm, the separation between the main peak and the impurity C peak in the spiked mixed solution should meet the requirements. The change rate of the detected amount of impurity C in the spiked mixed solution should be less than 20%.

[0179] 9.2 Test results

[0180] Under the conditions of flow rate change of ±0.1ml / min, column temperature change of ±2℃, and detection wavelength change of ±2nm, in the spiked mixed solution, the separation degree between impurity C and the main peak was at least 1.97, which was greater than 1.5; the maximum change rate of the detection amount of impurity C was 14.51%, which was less than 20%, and the durability was good.

[0181] (III) The verification results are summarized in Table 11

[0182] Table 11 Summary of verification results

[0183]

[0184]

[0185] In summary, the method for detecting impurity C of peramivir injection of the present invention has passed the tests of specificity, linearity and range, accuracy test, repeatability test, intermediate precision test, solution stability test and durability test, and is well adapted to the detection of impurity C of peramivir injection, which is helpful to improve the quality control level of peramivir injection.

[0186] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for detecting impurity C in peramivir injection, characterized in that: The following steps are involved: High performance liquid chromatography was used for detection, and the measurement conditions included: detection wavelength: 203-207 nm, column temperature: 18-22° C., flow rate: 0.2-0.4 ml / min; The model of the chromatographic column is CHIRALPAK AGP; the specification of the chromatographic column is 150 mm×4.0 mm, 5 μm; Mobile phase: phosphate buffer, wherein the phosphate buffer contains 4.75-5.25 mmol / L diammonium hydrogen phosphate and 4.75-5.25 mmol / L monoammonium dihydrogen phosphate; Preparation of test solution: Accurately measure the peramivir injection solution, dilute it with solvent to a solution containing 0.4-0.6 mg of peramivir per 1 ml, and mix well; The structure of impurity C is as follows:

2. The method for detecting impurity C in peramivir injection according to claim 1, characterized in that: Solution preparation includes: Impurity C localization solution: Take impurity C, weigh accurately, add solvent to dissolve and dilute to a solution containing 0.015-0.025 mg per 1 ml; Control solution: Accurately measure the test solution, dilute it with solvent to a solution containing 0.8-1.2 μg of peramivir per 1 ml, and mix well.

3. The method for detecting impurity C in peramivir injection according to claim 2, characterized in that: Determination method: Accurately measure the test solution, control solution, impurity C positioning solution and blank solvent, inject them into the liquid chromatograph respectively, and record the chromatogram; the injection volume is: 3-5μl.

4. The method for detecting impurity C in peramivir injection according to claim 1, characterized in that: Mobile phase: phosphate buffer, wherein the phosphate buffer contains 5 mmol / L diammonium hydrogen phosphate and 5 mmol / L monoammonium phosphate buffer.

5. The method for detecting impurity C in peramivir injection according to claim 1, characterized in that: Detection wavelength: 205 nm, column temperature: 20°C, flow rate: 0.3 ml / min, injection volume: 4 μl.

6. The method for detecting impurity C in peramivir injection according to claim 2, characterized in that: Impurity C localization solution: Take impurity C, weigh accurately, add solvent to dissolve and dilute to a solution containing 0.02 mg per 1 ml; Test solution: Accurately measure the peramivir injection solution, dilute it with solvent to a solution containing 0.5 mg of peramivir per 1 ml, and mix well; Control solution: Accurately measure the test solution, dilute it with solvent to a solution containing 1 μg of peramivir per 1 ml, and mix well.

7. The method for detecting impurity C in peramivir injection according to any one of claims 1, 2 and 6, characterized in that: The solvent is water.

Citation Information

Patent Citations

  • Method for determining peramivir intermediate isomers by using high performance liquid chromatography

    CN111983074A

  • Preparation method and application of peramivir related substances

    CN112694421A

  • Method for detecting peramivir trihydrate by reversed-phase high performance liquid chromatography

    CN112763623A

  • Detection method of peramivir chiral isomer

    CN114384193A